- Home
- GYRE vs AMSF Comparison
GYRE vs AMSF Comparison
Compare GYRE & AMSF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GYRE
- AMSF
- Stock Information
- Founded
- GYRE 2002
- AMSF 1985
- Country
- GYRE United States
- AMSF United States
- Employees
- GYRE N/A
- AMSF N/A
- Industry
- GYRE Biotechnology: Pharmaceutical Preparations
- AMSF Accident &Health Insurance
- Sector
- GYRE Health Care
- AMSF Finance
- Exchange
- GYRE Nasdaq
- AMSF Nasdaq
- Market Cap
- GYRE 897.1M
- AMSF 936.5M
- IPO Year
- GYRE N/A
- AMSF 2005
- Fundamental
- Price
- GYRE $9.53
- AMSF $47.19
- Analyst Decision
- GYRE
- AMSF Buy
- Analyst Count
- GYRE 0
- AMSF 2
- Target Price
- GYRE N/A
- AMSF $59.50
- AVG Volume (30 Days)
- GYRE 105.9K
- AMSF 104.6K
- Earning Date
- GYRE 05-09-2025
- AMSF 04-29-2025
- Dividend Yield
- GYRE N/A
- AMSF 9.55%
- EPS Growth
- GYRE N/A
- AMSF N/A
- EPS
- GYRE 0.04
- AMSF 2.48
- Revenue
- GYRE $100,643,000.00
- AMSF $301,216,000.00
- Revenue This Year
- GYRE $22.01
- AMSF $3.37
- Revenue Next Year
- GYRE $88.14
- AMSF $4.81
- P/E Ratio
- GYRE $213.36
- AMSF $19.07
- Revenue Growth
- GYRE N/A
- AMSF N/A
- 52 Week Low
- GYRE $6.11
- AMSF $41.97
- 52 Week High
- GYRE $19.00
- AMSF $60.24
- Technical
- Relative Strength Index (RSI)
- GYRE 55.67
- AMSF 42.50
- Support Level
- GYRE $8.51
- AMSF $46.34
- Resistance Level
- GYRE $9.98
- AMSF $47.90
- Average True Range (ATR)
- GYRE 0.61
- AMSF 1.64
- MACD
- GYRE 0.10
- AMSF -0.06
- Stochastic Oscillator
- GYRE 73.84
- AMSF 37.66
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
About AMSF AMERISAFE Inc.
AMERISAFE Inc is a specialty provider of workers' compensation insurance focused on small to mid-sized employers engaged in hazardous industries, principally construction, trucking, logging and lumber, agriculture, manufacturing, maritime, and telecommunications. The company generates a majority of its revenue in the form of premiums.